Intuitive Investments Group plc Investment in CardiNor AS (1435U)
March 31 2021 - 6:00AM
UK Regulatory
TIDMIIG
RNS Number : 1435U
Intuitive Investments Group plc
31 March 2021
31 March 2021
Intuitive Investments Group plc
Investment in CardiNor AS
Intuitive Investments Group plc (AIM: IIG) ("IIG" or the
"Company"), a closed-end investment company focussed on the life
sciences sector, announces an investment of GBP125,000 to acquire
ordinary shares in CardiNor AS ("CardiNor"), representing a 1.8 per
cent. interest in CardiNor's enlarged share capital.
CardiNor is a Norwegian biotech company established in June 2015
to commercialise the development of secretoneurin ("SN"), an
important new biomarker for cardiovascular disease ("CVD"). SN is
the only biomarker shown to be associated with biological processes
linked to cardiomyocyte handling. This unique biological function
explains why SN presents as an independent and strong predictor of
mortality in all major patient cohorts, including ventricular
arrhythmia, acute heart failure, acute respiratory failure patients
with CVD and severe sepsis. CardiNor has completed development of a
research assay based on immunoassay technology to measure SN in
blood and the assay is under further clinical development,
including to obtain a CE mark. More information can be found at:
https://cardinor.com/ .
In the year ended 31 December 2020 , per CardiNor's unaudited
management accounts, it achieved a loss after tax of approximately
GBP141,000 and, as at 31 December 2020, had net assets of
approximately GBP500,000, assuming an exchange rate of
11.87NOK/GBP.
For further information, please contact:
Intuitive Investments Group plc www.iigplc.com
David Evans, Executive Chairman Via Walbrook PR
Robert Naylor, CEO
Strand Hanson Limited - Nominated
Adviser +44 (0) 20 7409 3494
James Harris / James Dance / James
Bellman
Turner Pope Investments (TPI) Ltd
- Broker +44 (0) 20 3657 0050
Andrew Thacker / Zoe Alexander
Walbrook PR Limited - Media & Investor +44 (0)20 7933 8780 or intuitive@walbrookpr.com
Relations
+44 (0)7502 558 258 / +44 (0) 7980
Sam Allen / Paul McManus 541 893
About Intuitive Investments Group plc
The Company is a newly established investing company, seeking to
provide investors with exposure to a portfolio concentrating on
fast growing and/or high potential Life Sciences businesses
operating predominantly in the UK, continental Europe and the US,
utilising the Board's experience and in particular that of the
Chairman, David Evans, to seek to generate capital growth over the
long term for shareholders.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBFLFXFXLEBBQ
(END) Dow Jones Newswires
March 31, 2021 07:00 ET (11:00 GMT)
Intuitive Investments (LSE:IIG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intuitive Investments (LSE:IIG)
Historical Stock Chart
From Apr 2023 to Apr 2024